Key facts
- R3 Vascular’s last known valuation is $145.0M.
- It has raised $105.6M across 2 recorded rounds; the latest was Later Stage VC ($72.5M) in Apr 2024.
- Notable investors include Deerfield Management, 415 Capital, M&L Group, MedFocus, Philips Ventures — 6 tracked in total.
- R3 Vascular has filed 2 Form Ds with the SEC since 2020, most recently Sep 2024 ($72.5M sold to 34 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for R3 Vascular
Funding rounds
2 roundsAbout R3 Vascular
Developer of medical metallic stents devices designed to treat peripheral arterial diseases. The company offers bioresorbable vascular scaffolds, and BVS technology with a sirolimus coating which has anti-inflammatory properties, enabling physicians to treat peripheral arterial disease below the knee.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2019
- Employees
- 22
- Website
- r3vascular.com/
- Ownership
- Privately Held (backing)
R3 Vascular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in R3 Vascular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on R3 Vascular in its N-PORT filings yet. We sweep new filings monthly.